Women with early breast cancer now have a tool that can help individualize their treatment choices. Oncotype DX™ is a test that can help predict whether a woman with hormone-positive breast cancer that has not spread to her axillary (under the arm) lymph nodes will benefit from chemotherapy.

Tamoxifen, an anti-estrogen, plays an important role in both the treatment and prevention of breast cancer among women at high risk of the disease. Because treatment with tamoxifen involves some risks, however, researchers continue to evaluate long-term health effects. An important goal of this research is to identify women who are most likely to benefit from [...]

More just might be better when it comes to chemotherapy for patients with early-stage breast cancer. While it's recognized that a reduction in prescribed chemotherapy dosage and frequency can adversely impact a patient's chance of survival, results now indicate that doses given more often may increase survival in some individuals. Although it seems logical that doses [...]